Expression of SLC25A18 is positively correlated with Alzheimer's disease

Abstract Background: According to research, the neurotoxicity caused by the accumulation of the excitatory neurotransmitter glutamate is closely related to Alzheimer's disease. However, even after 50 years of research, little is known about the relationship between glutamate-related carriers and Alzheimer's disease, and it is unclear whether glutamate metabolism target genes are involved in the occurrence and development of AD.As a result, the goal of our investigations was to identify glutamate metabolism target genes involved in the onset and progression of AD, as well as to validate and mine the relationship between them. Results: In this paper, we analysed the Gene Expression Omnibus (GEO) data further and discovered that the expression of glutamate carrier SLC25A18 is correlated with Alzheimer's disease by screening the differential genes in different regions of the brain of Alzheimer's disease patients. To verify the expression of SLC25A18 during Alzheimer's disease development, we created animal models (5×FAD transgenic AD animal model, chemically induced AD animal model, natural ageing animal model), and the results showed that the expression of SLC25A18 increased when Alzheimer's disease occurred in various animal models. After that, we checked the expression of SLC25A18 in Aβ1-42-induced Neuro 2A cells, and the results revealed that neurons had higher SLC25A18 expression after Aβ1-42 induction. Conclusions: The results indicate that SLC25A18 is related to the onset and progression of Alzheimer's disease and that it could be a target for treatment.